Tag: CPAP Therapy
BleepSleep launches new Shopify-powered storefront
June 2, 2026HME News Staff
CHAPEL HILL, N.C. – BleepSleep has launched a redesigned, direct-to-consumer Shopify store at bleepsleep.com for its mask-less, strap-free CPAP solutions, the DreamPort and Eclipse. "Too many CPAP users abandon therapy not because therapy doesn't work - but because the mask makes it unbearable,” said Stuart Heatherington, founder and CEO. “DreamPort and Eclipse were designed from the ground up to solve that. No headgear. No straps. No leaks. Just therapy that patients can...
LiViliti Health Products receives FDA clearance for CPAP sanitizer
May 4, 2026HME News Staff
SARASOTA, Fla. – LiViliti Health Products has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Paptizer 360. Classified as a Class II Respiratory Accessory Microbial Reduction Device, the Paptizer 360 provides a supplemental, at-home bacterial reduction process on compatible CPAP equipment. "This clearance marks a significant milestone for LiViliti as we continue to provide users with scientifically validated tools for their respiratory health," said...
Providers expect pick up in sleep patient volume
April 29, 2026HME News Staff
NEW YORK – Providers saw slower sleep patient volume in the last 12 months but expect improved growth in the next 12 months, according to the 1Q26 HME Sleep and Oxygen Survey from Needham.
Other sleep-related findings from the survey:
Resmed looks likely to lose flow generator market share to React Health and modest mask market share to React Health and Fisher & Paykel Healthcare in the next 12 months.
Respondents expect to shift a moderate portion of their flow generator purchases...
In brief: OIG’s PAP investigation, Oz’s Medicaid revalidation initiative, CCS’s agentic AI platform
April 27, 2026HME News Staff
WASHINGTON - Medicare payments made to suppliers for PAP devices generally complied with Medicare billing requirements, according to a new report from the Office of Inspector General (OIG).
For fiscal year 2017, the Comprehensive Error Rate Testing (CERT) Program determined continuous PAP (CPAP) devices had the second highest improper payment amount in the DMEPOS category, with estimated improper payments totaling $495 million for CPAP devices used for the treatment of obstructive sleep apnea...
AASM asks UnitedHealthcare to address delays in PAP and respiratory fulfillment
April 13, 2026HME News Staff
DARIEN, Ill. – The American Academy of Sleep Medicine (AASM) recently sent a letter to UnitedHealthcare, raising concerns about the payer’s use of Synapse Health for durable medical equipment (DME) fulfillment for CPAP therapy.
“AASM members report that operational barriers associated with Synapse Health have delayed initiation of medically necessary therapy and created avoidable administrative burden for patients, clinicians, and DME suppliers, particularly related to treatment...
Researchers develop algorithm to predict impact of CPAP therapy on cardiovascular disease
April 13, 2026HME News Staff
NEW YORK – Researchers at Mount Sinai have created an analytic tool using machine learning that they say can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, according to findings recently published in Communications Medicine.
The researchers used a machine learning algorithm to create an analysis model that they say predicts how CPAP could affect an individual’s cardiovascular health – estimating each patient’s likeliness of benefit...
Resmed reports 11% increase in revenues for Q2
January 29, 2026HME News Staff
SAN DIEGO – Resmed reported revenue increased 11% to $1.4 billion for its second quarter of fiscal year 2026.
Other financial results:
Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%.
Income from operations increased 18%; non-GAAP income from operations up 19%.
Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81.
Operating cash flow of $340 million.
“Our...
Resmed highlights AI-driven CPAP tech, competitive bidding win and GLP-1 insights at J.P. Morgan Healthcare Conference
January 16, 2026Liz Beaulieu, Editor
SAN FRANCISCO – Resmed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Smart Comfort, will help improve both short- and long-term compliance with therapy.
Resmed announced in late 2025 that the U.S. Food and Drug Administration (FDA) had cleared Smart Comfort. The technology will launch in a limited beta in early 2026 for new...
Study links untreated OSA with accelerated cardiovascular aging
December 17, 2025HME News Staff
COLUMBIA, Mo. - Researchers at the University of Missouri School of Medicine and the Marshall University Joan C. Edwards School of Medicine have found evidence that untreated obstructive sleep apnea (OSA) accelerates cardiovascular aging and significantly increases the risk of premature death.
Study design
Researchers, led by David Gozal, MD, MBA, PhD (Hon), vice president of health affairs at Marshall University and dean of the Joan C. Edwards...
Resmed receives FDA clearance for AI-enabled CPAP settings
December 8, 2025HME News Staff
SAN DIEGO – Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled device that recommends personalized comfort settings to help people with obstructive sleep apnea (OSA) start and stay on CPAP therapy.
Personalized Therapy Comfort Settings (PTCS), which will be marketed as Smart Comfort, will launch in early 2026 in a limited beta version in the United States for new users of myAir paired...